Barclays PLC Purchases 50,109 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Barclays PLC boosted its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 29.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 218,455 shares of the biotechnology company’s stock after buying an additional 50,109 shares during the period. Barclays PLC owned approximately 0.14% of Heron Therapeutics worth $434,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Clearline Capital LP raised its stake in Heron Therapeutics by 48.9% during the third quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock valued at $4,431,000 after purchasing an additional 731,246 shares in the last quarter. Congress Park Capital LLC lifted its holdings in shares of Heron Therapeutics by 25.3% in the 3rd quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock valued at $3,936,000 after acquiring an additional 399,577 shares during the last quarter. Marshall Wace LLP grew its position in Heron Therapeutics by 256.2% in the second quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock worth $6,164,000 after acquiring an additional 1,266,697 shares in the last quarter. AQR Capital Management LLC increased its stake in Heron Therapeutics by 1,460.9% during the second quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock worth $2,125,000 after acquiring an additional 568,238 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its stake in shares of Heron Therapeutics by 18.4% in the 3rd quarter. GSA Capital Partners LLP now owns 512,736 shares of the biotechnology company’s stock valued at $1,020,000 after purchasing an additional 79,680 shares during the last quarter. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Stock Performance

Shares of HRTX stock opened at $1.63 on Friday. The stock has a 50 day moving average price of $1.47 and a 200 day moving average price of $1.95. Heron Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $3.93. The firm has a market capitalization of $247.92 million, a P/E ratio of -9.06 and a beta of 1.60.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). The business had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same quarter last year, the business posted ($0.17) earnings per share. As a group, sell-side analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Wall Street Analysts Forecast Growth

HRTX has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $4.00 price target on shares of Heron Therapeutics in a report on Wednesday, December 4th. StockNews.com downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.